Hycodan (homatropine / hydrocodone) and Alcohol / Food Interactions
There are 2 alcohol/food/lifestyle interactions with Hycodan (homatropine / hydrocodone) which include:
HYDROcodone ↔ food
Major Food Interaction
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including hydrocodone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.
GENERALLY AVOID: Consumption of alcohol while taking some sustained-release formulations of hydrocodone may cause rapid release of the drug, resulting in high systemic levels of hydrocodone that may be potentially lethal. Alcohol apparently can disrupt the release mechanism of some sustained-release formulations. In study subjects, the rate of absorption of hydrocodone from an extended-release formulation was found to be affected by coadministration with 40% alcohol in the fasted state, as demonstrated by an average 2.4-fold (up to 3.9-fold in one subject) increase in hydrocodone peak plasma concentration and a decrease in the time to peak concentration. Alcohol also increased the extent of absorption by an average of 1.2-fold (up to 1.7-fold in one subject).
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of hydrocodone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of hydrocodone by certain compounds present in grapefruit. Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.
MANAGEMENT: Patients taking sustained-release formulations of hydrocodone should not consume alcohol or use medications that contain alcohol. In general, potent narcotics such as hydrocodone should not be combined with alcohol. Patients should also avoid consumption of grapefruit or grapefruit juice during treatment with hydrocodone.
- "Product Information. Zohydro ER (HYDROcodone)." Zogenix, Inc, San Diego, CA.
High Blood Pressure (Hypertension)
Minor Potential Hazard, Low plausibility
anticholinergics - hypertension
Cardiovascular effects of anticholinergics may exacerbate hypertension. Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.
- "Product Information. Marezine (cyclizine)." Glaxo Wellcome, Research Triangle Park, NC.
- "Product Information. Benadryl (diphenhydramine)." Parke-Davis, Morris Plains, NJ.
- "Product Information. Cogentin (benztropine)." Merck & Co, Inc, West Point, PA.
- "Product Information. Artane (trihexyphenidyl)." Lederle Laboratories, Wayne, NJ.
- Valentin N, Staffeldt H, Kyst A "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand 28 (1984): 621-4
- "Product Information. Atropine Sulfate Injection, USP (atropine)." ESI Lederle Generics, Philadelphia, PA.
- "Product Information. Antivert (meclizine)." Roerig Division, New York, NY.
Hycodan (homatropine / hydrocodone) drug Interactions
There are 1034 drug interactions with Hycodan (homatropine / hydrocodone)
Hycodan (homatropine / hydrocodone) disease Interactions
There are 33 disease interactions with Hycodan (homatropine / hydrocodone) which include:
- Autonomic Neuropathy
- Gi Obstruction
- Obstructive Uropathy
- Reactive Airway Diseases
- Myasthenia Gravis
- Infectious Diarrhea
- Impaired Gi Motility
- Infectious Diarrhea
- Liver Disease
- Renal Dysfunction
- Acute Alcohol Intoxication
- Drug Dependence
- Intracranial Pressure
- Respiratory Depression
- Cardiac Disease
- Coronary Artery Disease
- Gastric Ulcer
- Gastroesophageal Reflux
- Ulcerative Colitis
- Adrenal Insufficiency
- Biliary Spasm
- Seizure Disorders
- Urinary Retention
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.